Physitrack: Preview Q3 2024e - Redeye

Redeye anticipates the Lifecare division to maintain its solid performance in Q3 2024, though weaker results from the Wellness division will likely limit overall growth. However, the stable ARR growth is expected to persist, along with a rebound to positive cash flow. Physitrack’s Q3 2024 report is set to be released on 12 November at 08:00, followed by a conference call at 14:00. We maintain our fair value range with a Base case valuation of SEK30 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045148/physitrack-preview-q3-2024e?utm_source=finwire&utm_medium=RSS